The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RX | +26.09% | +88.82% | +13.56% | +1,201% |
| S&P | +15.58% | +78.13% | +12.24% | +2,514% |
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include Cathejell Jelly, FeraMAX Pd Therapeutic 150, FeraMAX Pd Powder 15, Proktis-M, RepaGyn, and cTIBELLA. The company was founded on April 28, 1947 and is headquartered in Mississauga, Canada.
No news articles found for BioSyent.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.22M | 27.9% |
| Gross Profit | $9.06M | 23.0% |
| Gross Margin | 74.17% | -3.0% |
| Market Cap | $132.43M | 4.9% |
| Market Cap / Employee | $2.21M | 0.0% |
| Employees | 60 | 0.0% |
| Net Income | $2.68M | 16.2% |
| EBITDA | $3.61M | 30.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.03M | 36.3% |
| Accounts Receivable | $5.53M | 42.3% |
| Inventory | 5.9 | 4.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $681.30K | -23.7% |
| Short Term Debt | $211.58K | 10.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 18.52% | 2.2% |
| Return On Invested Capital | 17.31% | 0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.77M | -59.9% |
| Operating Free Cash Flow | $2.78M | -60.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.46 | 16.29 | 16.22 | 15.06 | -14.14% |
| Price to Book | 3.41 | 3.59 | 3.69 | 3.46 | -1.35% |
| Price to Sales | 3.54 | 3.35 | 3.43 | 3.15 | -14.20% |
| Price to Tangible Book Value | 4.03 | 4.20 | 4.28 | 3.97 | 9.50% |
| Price to Free Cash Flow TTM | 16.18 | 19.04 | 13.14 | 21.64 | 1.09% |
| Enterprise Value to EBITDA | 50.41 | 35.44 | 41.83 | 30.53 | -23.31% |
| Free Cash Flow Yield | 6.2% | 5.3% | 7.6% | 4.6% | -1.08% |
| Return on Equity | 20.8% | 22.2% | 22.6% | 22.4% | 13.05% |
| Total Debt | $1.04M | $990.22K | $942.23K | $892.88K | -17.66% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
